Scpharmaceuticals Total Assets vs Other Current Liab Analysis

SCPH Stock  USD 4.21  0.11  2.55%   
Scpharmaceuticals financial indicator trend analysis is much more than just breaking down Scpharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Scpharmaceuticals is a good investment. Please check the relationship between Scpharmaceuticals Total Assets and its Other Current Liab accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.

Total Assets vs Other Current Liab

Total Assets vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Scpharmaceuticals Total Assets account and Other Current Liab. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Scpharmaceuticals' Total Assets and Other Current Liab is 0.43. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Scpharmaceuticals, assuming nothing else is changed. The correlation between historical values of Scpharmaceuticals' Total Assets and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Scpharmaceuticals are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Total Assets i.e., Scpharmaceuticals' Total Assets and Other Current Liab go up and down completely randomly.

Correlation Coefficient

0.43
Relationship DirectionPositive 
Relationship StrengthWeak

Total Assets

Total assets refers to the total amount of Scpharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Scpharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Other Current Liab

Most indicators from Scpharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Scpharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.As of now, Scpharmaceuticals' Selling General Administrative is increasing as compared to previous years. The Scpharmaceuticals' current Enterprise Value is estimated to increase to about 246.7 M, while Issuance Of Capital Stock is projected to decrease to under 31.9 M.
 2021 2022 2023 2024 (projected)
Interest Expense2.6M3.3M8.1M8.5M
Depreciation And Amortization438K468K626K502.9K

Scpharmaceuticals fundamental ratios Correlations

0.430.72-0.290.490.940.83-0.73-0.770.50.940.870.860.531.00.620.550.10.90.40.430.340.270.610.91.0
0.430.460.040.890.360.30.21-0.80.910.230.310.170.10.390.850.690.470.570.860.910.830.550.430.350.43
0.720.46-0.360.510.740.52-0.39-0.860.50.630.570.730.40.690.790.840.050.880.480.510.470.280.590.760.72
-0.290.04-0.360.04-0.20.090.260.280.33-0.25-0.01-0.52-0.57-0.31-0.03-0.460.01-0.380.330.240.46-0.08-0.23-0.33-0.29
0.490.890.510.040.420.320.22-0.830.850.230.320.35-0.130.450.870.70.430.620.850.950.820.530.490.350.49
0.940.360.74-0.20.420.9-0.71-0.730.440.90.930.840.520.930.590.54-0.180.910.410.40.360.00.650.790.94
0.830.30.520.090.320.9-0.7-0.550.460.840.990.630.310.820.420.31-0.150.720.480.380.41-0.020.710.740.83
-0.730.21-0.390.260.22-0.71-0.70.190.07-0.88-0.73-0.65-0.65-0.76-0.02-0.010.19-0.490.180.240.210.1-0.27-0.72-0.73
-0.77-0.8-0.860.28-0.83-0.73-0.550.19-0.76-0.59-0.59-0.68-0.29-0.73-0.94-0.88-0.25-0.91-0.75-0.8-0.69-0.44-0.67-0.7-0.77
0.50.910.50.330.850.440.460.07-0.760.340.440.19-0.020.450.880.550.450.550.930.940.950.550.40.430.5
0.940.230.63-0.250.230.90.84-0.88-0.590.340.880.820.620.960.450.34-0.060.760.240.210.190.090.50.850.94
0.870.310.57-0.010.320.930.99-0.73-0.590.440.880.710.390.860.450.36-0.160.770.460.360.37-0.020.720.780.87
0.860.170.73-0.520.350.840.63-0.65-0.680.190.820.710.430.870.480.5-0.150.810.20.230.110.020.580.730.86
0.530.10.4-0.57-0.130.520.31-0.65-0.29-0.020.620.390.430.560.180.31-0.190.48-0.19-0.17-0.22-0.090.050.460.53
1.00.390.69-0.310.450.930.82-0.76-0.730.450.960.860.870.560.580.50.080.880.350.370.290.240.570.881.0
0.620.850.79-0.030.870.590.42-0.02-0.940.880.450.450.480.180.580.80.260.760.830.90.840.440.480.520.62
0.550.690.84-0.460.70.540.31-0.01-0.880.550.340.360.50.310.50.80.240.820.580.650.510.430.660.580.55
0.10.470.050.010.43-0.18-0.150.19-0.250.45-0.06-0.16-0.15-0.190.080.260.240.080.280.370.280.970.040.320.11
0.90.570.88-0.380.620.910.72-0.49-0.910.550.760.770.810.480.880.760.820.080.520.560.450.280.710.840.9
0.40.860.480.330.850.410.480.18-0.750.930.240.460.2-0.190.350.830.580.280.520.960.970.380.60.340.4
0.430.910.510.240.950.40.380.24-0.80.940.210.360.23-0.170.370.90.650.370.560.960.950.470.50.320.43
0.340.830.470.460.820.360.410.21-0.690.950.190.370.11-0.220.290.840.510.280.450.970.950.380.430.270.34
0.270.550.28-0.080.530.0-0.020.1-0.440.550.09-0.020.02-0.090.240.440.430.970.280.380.470.380.170.480.27
0.610.430.59-0.230.490.650.71-0.27-0.670.40.50.720.580.050.570.480.660.040.710.60.50.430.170.660.61
0.90.350.76-0.330.350.790.74-0.72-0.70.430.850.780.730.460.880.520.580.320.840.340.320.270.480.660.9
1.00.430.72-0.290.490.940.83-0.73-0.770.50.940.870.860.531.00.620.550.110.90.40.430.340.270.610.9
Click cells to compare fundamentals

Scpharmaceuticals Account Relationship Matchups

Scpharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets77.3M109.0M79.0M124.2M94.5M90.6M
Other Current Liab3.7M4.8M26K5.3M9.0M9.4M
Total Current Liabilities5.2M9.3M14.8M7.4M13.1M8.3M
Total Stockholder Equity(129.5M)(161.7M)(189.7M)(226.5M)37.2M39.1M
Other Liab58K219K367K7.5M8.7M9.1M
Net Tangible Assets51.4M82.2M63.1M72.4M83.3M54.8M
Property Plant And Equipment Net1.3M908K479K620K1.5M1.0M
Net Debt(52.5M)(85.1M)(56.6M)(33.7M)(6.5M)(6.9M)
Retained Earnings(129.5M)(161.7M)(189.7M)(226.5M)(281.3M)(267.3M)
Accounts Payable1.1M1.7M544K1.5M4.0M4.2M
Cash72.8M105.3M74.3M71.1M46.8M75.7M
Non Current Assets Total1.6M1.2M762K887K1.5M1.2M
Non Currrent Assets Other148K132K283K267K82.0K159.4K
Other Assets330K1.1M283K267K1.00.95
Cash And Short Term Investments72.8M105.3M75.5M118.4M76.0M85.2M
Net Receivables655K479K310K2.3M4.5M4.7M
Common Stock Shares Outstanding18.6M24.6M27.4M28.4M38.5M22.2M
Liabilities And Stockholders Equity(103.5M)(134.8M)(167.1M)(174.8M)94.5M99.2M
Non Current Liabilities Total20.7M17.6M7.7M44.3M44.1M29.9M
Capital Surpluse180.8M243.8M246.2M298.9M343.8M182.1M
Inventory1.6M2.4M0.01.2M8.8M9.3M
Other Current Assets94K121K24K1.4M3.6M3.8M
Other Stockholder Equity598K(2K)(4K)(35K)318.6M334.5M
Total Liab25.9M26.9M22.6M51.8M57.3M38.2M
Property Plant And Equipment Gross1.3M93K649K808K1.5M769.8K
Total Current Assets75.6M107.8M78.3M123.3M92.9M89.4M
Accumulated Other Comprehensive Income(600K)(102K)1K(1K)32K(1.1K)
Property Plant Equipment1.3M908K69K54K48.6K46.2K
Non Current Liabilities Other58K219K367K35K177K147.7K
Short Long Term Debt Total20.3M20.2M17.6M37.4M40.3M24.9M
Long Term Debt18.9M16.9M7.4M36.8M38.8M21.2M
Long Term Debt Total18.9M16.9M7.4M36.8M42.3M44.4M
Capital Lease Obligations1.4M940K476K574K1.5M963.3K
Net Invested Capital70.3M101.4M73.6M109.2M76.0M72.5M
Net Working Capital70.4M98.5M63.4M115.9M79.8M71.8M
Short Term Debt407K2.9M10.3M567K176K167.2K

Currently Active Assets on Macroaxis

When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.56)
Revenue Per Share
0.619
Quarterly Revenue Growth
3.917
Return On Assets
(0.42)
Return On Equity
(1.67)
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.